AU2023216993A1 - Morphic forms of cft7455 and methods of manufacture thereof - Google Patents
Morphic forms of cft7455 and methods of manufacture thereof Download PDFInfo
- Publication number
- AU2023216993A1 AU2023216993A1 AU2023216993A AU2023216993A AU2023216993A1 AU 2023216993 A1 AU2023216993 A1 AU 2023216993A1 AU 2023216993 A AU2023216993 A AU 2023216993A AU 2023216993 A AU2023216993 A AU 2023216993A AU 2023216993 A1 AU2023216993 A1 AU 2023216993A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- certain embodiments
- pharmaceutical composition
- administered
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210119643.2 | 2022-02-09 | ||
| CN202210119643 | 2022-02-09 | ||
| US202263308883P | 2022-02-10 | 2022-02-10 | |
| US63/308,883 | 2022-02-10 | ||
| US202263328659P | 2022-04-07 | 2022-04-07 | |
| US63/328,659 | 2022-04-07 | ||
| US202363437718P | 2023-01-08 | 2023-01-08 | |
| US63/437,718 | 2023-01-08 | ||
| PCT/US2023/012734 WO2023154417A1 (en) | 2022-02-09 | 2023-02-09 | Morphic forms of cft7455 and methods of manufacture thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023216993A1 true AU2023216993A1 (en) | 2024-07-25 |
Family
ID=87565017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023216993A Pending AU2023216993A1 (en) | 2022-02-09 | 2023-02-09 | Morphic forms of cft7455 and methods of manufacture thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240391912A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4476217A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505687A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240146048A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023216993A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3247460A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314625A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009897A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023154417A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6504034B2 (en) * | 2001-01-23 | 2003-01-07 | Hoffmann-La Roche Inc. | Naphthostyrils |
| CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| JP7629459B2 (ja) * | 2019-11-19 | 2025-02-13 | ブリストル-マイヤーズ スクイブ カンパニー | Heliosタンパク質の阻害剤として有用な化合物 |
| AU2021322285B2 (en) * | 2020-08-07 | 2026-08-13 | C4 Therapeutics, Inc. | Advantageous therapies for disorders mediated by Ikaros or Aiolos |
| CN118201612A (zh) * | 2021-08-04 | 2024-06-14 | 上海睿跃生物科技有限公司 | 用于治疗淋巴瘤的组合疗法的组合物和方法 |
| JP7807110B2 (ja) * | 2021-08-27 | 2026-01-27 | ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド | イソインドリノン化合物およびその使用 |
-
2023
- 2023-02-09 JP JP2024547223A patent/JP2025505687A/ja active Pending
- 2023-02-09 WO PCT/US2023/012734 patent/WO2023154417A1/en not_active Ceased
- 2023-02-09 AU AU2023216993A patent/AU2023216993A1/en active Pending
- 2023-02-09 CA CA3247460A patent/CA3247460A1/en active Pending
- 2023-02-09 EP EP23753451.6A patent/EP4476217A4/en active Pending
- 2023-02-09 KR KR1020247029748A patent/KR20240146048A/ko active Pending
- 2023-02-09 MX MX2024009897A patent/MX2024009897A/es unknown
- 2023-02-09 IL IL314625A patent/IL314625A/en unknown
-
2024
- 2024-08-07 US US18/797,261 patent/US20240391912A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024009897A (es) | 2024-08-20 |
| WO2023154417A1 (en) | 2023-08-17 |
| EP4476217A4 (en) | 2026-01-21 |
| CA3247460A1 (en) | 2023-08-17 |
| IL314625A (en) | 2024-09-01 |
| EP4476217A1 (en) | 2024-12-18 |
| JP2025505687A (ja) | 2025-02-28 |
| US20240391912A1 (en) | 2024-11-28 |
| KR20240146048A (ko) | 2024-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230190760A1 (en) | Advantageous therapies for disorders mediated by ikaros or aiolos | |
| US20240245677A1 (en) | Selected compounds for targeted degradation of brd9 | |
| US20230043305A1 (en) | Morphic forms of g1t38 and methods of manufacture thereof | |
| US12479855B2 (en) | Morphic forms of trilaciclib and methods of manufacture thereof | |
| KR20180113976A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| US20240391912A1 (en) | Morphic forms of cft7455 and methods of manufacture thereof | |
| TWI906312B (zh) | 曲拉西利(trilaciclib)之型態形式及製造方法 | |
| EP4611901A1 (en) | Ret-ldd protein degraders | |
| RU2844734C1 (ru) | Преимущественные терапии нарушений, опосредованных ikaros или aiolos | |
| US20250289827A1 (en) | Morphic forms of a mutant braf degrader and methods of manufacture thereof | |
| CN118660884A (zh) | Cft7455的晶型物及其制造方法 | |
| CA3174290A1 (en) | Selected compounds for targeted degradation of brd9 | |
| WO2024173832A2 (en) | Isoindolinone glutarimide and phenyl glutarimide analogs as degraders of ret kinase | |
| WO2025129116A1 (en) | Compounds for the targeted degradation of smarca2 | |
| JP2025540906A (ja) | Ret-lddタンパク質阻害剤 |